Theodore F. Logan, MD
Associate Professor of Clinical Medicine
Program Leader - Melanoma
- Address
-
Indiana Cancer Pavilion
535 Barnhill Dr., Suite 473
RT 473
Indianapolis, IN 46202-5289 - PubMed:
-
| Year | Degree | Institution |
|---|---|---|
| 1989 | Fellowship | University of Pittsburgh, Pittsburgh, PA |
| 1984 | Residency | University of Pittsburgh, Pittsburgh, PA |
| 1981 | MD | University of Vermont |
| 1974 | BA | Colby College |
My interest is in the use of biologic agents (cytokines, cells, vaccines, etc.) either with or without chemotherapy in the treatment of cancer, especially renal cell cancer.
A phase 2, randomized trial evaluating the combination of dalantercept plus axitinib in patients with advanced clear cell renal cell carcinoma.
Voss MH; Bhatt RS; Vogelzang NJ; Fishman M; Alter RS; Rini BI; Beck JT; Joshi M; Hauke R; Atkins MB; Burgess E; Logan TF; Shaffer D; Parikh R; Moazzam N; Zhang X; Glasser C; Sherman ML; Plimack ER; Cancer 2019 Apr 5
Voss MH; Bhatt RS; Vogelzang NJ; Fishman M; Alter RS; Rini BI; Beck JT; Joshi M; Hauke R; Atkins MB; Burgess E; Logan TF; Shaffer D; Parikh R; Moazzam N; Zhang X; Glasser C; Sherman ML; Plimack ER; Cancer 2019 Apr 5
NCI 8628: A randomized phase 2 study of ziv-aflibercept and high-dose interleukin 2 or high-dose interleukin 2 alone for inoperable stage III or IV melanoma.
Tarhini AA; Frankel P; Ruel C; Ernstoff MS; Kuzel TM; Logan TF; Khushalani NI; Tawbi HA; Margolin KA; Awasthi S; Butterfield LH; McDermott D; Chen A; Lara PN; Kirkwood JM; 2018 Oct 10
Tarhini AA; Frankel P; Ruel C; Ernstoff MS; Kuzel TM; Logan TF; Khushalani NI; Tawbi HA; Margolin KA; Awasthi S; Butterfield LH; McDermott D; Chen A; Lara PN; Kirkwood JM; 2018 Oct 10
A multi-center phase II study of high dose interleukin-2 sequenced with vemurafenib in patients with BRAF-V600 mutation positive metastatic melanoma.
Clark JI; Singh J; Ernstoff MS; Lao CD; Flaherty LE; Logan TF; Curti B; Agarwala SS; Taback B; Cranmer L; Lutzky J; Luna TL; Aung S; Lawson DH; 2018 Jul 27
Clark JI; Singh J; Ernstoff MS; Lao CD; Flaherty LE; Logan TF; Curti B; Agarwala SS; Taback B; Cranmer L; Lutzky J; Luna TL; Aung S; Lawson DH; 2018 Jul 27
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
Chesney J; Puzanov I; Collichio F; Singh P; Milhem MM; Glaspy J; Hamid O; Ross M; Friedlander P; Garbe C; Logan TF; Hauschild A; Lebbé C; Chen L; Kim JJ; Gansert J; Andtbacka RHI; Kaufman HL; Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Oct 5
Chesney J; Puzanov I; Collichio F; Singh P; Milhem MM; Glaspy J; Hamid O; Ross M; Friedlander P; Garbe C; Logan TF; Hauschild A; Lebbé C; Chen L; Kim JJ; Gansert J; Andtbacka RHI; Kaufman HL; Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Oct 5
Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma.
Chesney J; Puzanov I; Collichio F; Singh P; Milhem MM; Glaspy J; Hamid O; Ross M; Friedlander P; Garbe C; Logan TF; Hauschild A; Lebbé C; Chen L; Kim JJ; Gansert J; Andtbacka RHI; Kaufman HL; 2017 Oct 5
Chesney J; Puzanov I; Collichio F; Singh P; Milhem MM; Glaspy J; Hamid O; Ross M; Friedlander P; Garbe C; Logan TF; Hauschild A; Lebbé C; Chen L; Kim JJ; Gansert J; Andtbacka RHI; Kaufman HL; 2017 Oct 5
Improved survival and tumor control with Interleukin-2 is associated with the development of immune-related adverse events: data from the PROCLAIM<sup>SM</sup> registry.
Curti B; Daniels GA; McDermott DF; Clark JI; Kaufman HL; Logan TF; Singh J; Kaur M; Luna TL; Gregory N; Morse MA; Wong MKK; Dutcher JP; Journal for immunotherapy of cancer 2017 Dec 19
Curti B; Daniels GA; McDermott DF; Clark JI; Kaufman HL; Logan TF; Singh J; Kaur M; Luna TL; Gregory N; Morse MA; Wong MKK; Dutcher JP; Journal for immunotherapy of cancer 2017 Dec 19
Contemporary experience with high-dose interleukin-2 therapy and impact on survival in patients with metastatic melanoma and metastatic renal cell carcinoma.
Alva A; Daniels GA; Wong MK; Kaufman HL; Morse MA; McDermott DF; Clark JI; Agarwala SS; Miletello G; Logan TF; Hauke RJ; Curti B; Kirkwood JM; Gonzalez R; Amin A; Fishman M; Agarwal N; Lowder JN; Hua H; Aung S; Dutcher JP; Cancer immunology, immunotherapy : CII 2016 Oct 6
Alva A; Daniels GA; Wong MK; Kaufman HL; Morse MA; McDermott DF; Clark JI; Agarwala SS; Miletello G; Logan TF; Hauke RJ; Curti B; Kirkwood JM; Gonzalez R; Amin A; Fishman M; Agarwal N; Lowder JN; Hua H; Aung S; Dutcher JP; Cancer immunology, immunotherapy : CII 2016 Oct 6
Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody.
Segal NH; Logan TF; Hodi FS; McDermott D; Melero I; Hamid O; Schmidt H; Robert C; Chiarion-Sileni V; Ascierto PA; Maio M; Urba WJ; Gangadhar TC; Suryawanshi S; Neely J; Jure-Kunkel M; Krishnan S; Kohrt H; Sznol M; Levy R; Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Oct 18
Segal NH; Logan TF; Hodi FS; McDermott D; Melero I; Hamid O; Schmidt H; Robert C; Chiarion-Sileni V; Ascierto PA; Maio M; Urba WJ; Gangadhar TC; Suryawanshi S; Neely J; Jure-Kunkel M; Krishnan S; Kohrt H; Sznol M; Levy R; Clinical cancer research : an official journal of the American Association for Cancer Research 2016 Oct 18
Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial.
Weber JS; Gibney G; Sullivan RJ; Sosman JA; Slingluff CL Jr; Lawrence DP; Logan TF; Schuchter LM; Nair S; Fecher L; Buchbinder EI; Berghorn E; Ruisi M; Kong G; Jiang J; Horak C; Hodi FS; The Lancet. Oncology 2016 Jun 4
Weber JS; Gibney G; Sullivan RJ; Sosman JA; Slingluff CL Jr; Lawrence DP; Logan TF; Schuchter LM; Nair S; Fecher L; Buchbinder EI; Berghorn E; Ruisi M; Kong G; Jiang J; Horak C; Hodi FS; The Lancet. Oncology 2016 Jun 4
Everolimus versus sunitinib for patients with metastatic non-clear cell renal cell carcinoma (ASPEN): a multicentre, open-label, randomised phase 2 trial.
Armstrong AJ; Halabi S; Eisen T; Broderick S; Stadler WM; Jones RJ; Garcia JA; Vaishampayan UN; Picus J; Hawkins RE; Hainsworth JD; Kollmannsberger CK; Logan TF; Puzanov I; Pickering LM; Ryan CW; Protheroe A; Lusk CM; Oberg S; George DJ; The Lancet. Oncology 2016 Jan 12
Armstrong AJ; Halabi S; Eisen T; Broderick S; Stadler WM; Jones RJ; Garcia JA; Vaishampayan UN; Picus J; Hawkins RE; Hainsworth JD; Kollmannsberger CK; Logan TF; Puzanov I; Pickering LM; Ryan CW; Protheroe A; Lusk CM; Oberg S; George DJ; The Lancet. Oncology 2016 Jan 12
Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results.
Amin A; Dudek AZ; Logan TF; Lance RS; Holzbeierlein JM; Knox JJ; Master VA; Pal SK; Miller WH Jr; Karsh LI; Tcherepanova IY; DeBenedette MA; Williams WL; Plessinger DC; Nicolette CA; Figlin RA; Journal for immunotherapy of cancer 2015 Apr 21
Amin A; Dudek AZ; Logan TF; Lance RS; Holzbeierlein JM; Knox JJ; Master VA; Pal SK; Miller WH Jr; Karsh LI; Tcherepanova IY; DeBenedette MA; Williams WL; Plessinger DC; Nicolette CA; Figlin RA; Journal for immunotherapy of cancer 2015 Apr 21
Discordancy in BRAF mutations among primary and metastatic melanoma lesions: clinical implications for targeted therapy.
Bradish JR; Richey JD; Post KM; Meehan K; Sen JD; Malek AJ; Katona TM; Warren S; Logan TF; Fecher LA; Cheng L; Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2014 Nov 7
Bradish JR; Richey JD; Post KM; Meehan K; Sen JD; Malek AJ; Katona TM; Warren S; Logan TF; Fecher LA; Cheng L; Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2014 Nov 7
The high-dose aldesleukin "select" trial: a trial to prospectively validate predictive models of response to treatment in patients with metastatic renal cell carcinoma.
McDermott DF; Cheng SC; Signoretti S; Margolin KA; Clark JI; Sosman JA; Dutcher JP; Logan TF; Curti BD; Ernstoff MS; Appleman L; Wong MK; Khushalani NI; Oleksowicz L; Vaishampayan UN; Mier JW; Panka DJ; Bhatt RS; Bailey AS; Leibovich BC; Kwon ED; Kabbinavar FF; Belldegrun AS; Figlin RA; Pantuck AJ; Regan MM; Atkins MB; Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Nov 25
McDermott DF; Cheng SC; Signoretti S; Margolin KA; Clark JI; Sosman JA; Dutcher JP; Logan TF; Curti BD; Ernstoff MS; Appleman L; Wong MK; Khushalani NI; Oleksowicz L; Vaishampayan UN; Mier JW; Panka DJ; Bhatt RS; Bailey AS; Leibovich BC; Kwon ED; Kabbinavar FF; Belldegrun AS; Figlin RA; Pantuck AJ; Regan MM; Atkins MB; Clinical cancer research : an official journal of the American Association for Cancer Research 2014 Nov 25
Whole-body PET/CT evaluation of tumor perfusion using generator-based 62Cu-ethylglyoxal bis(thiosemicarbazonato)copper(II): validation by direct comparison to 15O-water in metastatic renal cell carcinoma.
Fletcher JW; Logan TF; Eitel JA; Mathias CJ; Ng Y; Lacy JL; Hutchins GD; Green MA; Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2014 Dec 18
Fletcher JW; Logan TF; Eitel JA; Mathias CJ; Ng Y; Lacy JL; Hutchins GD; Green MA; Journal of nuclear medicine : official publication, Society of Nuclear Medicine 2014 Dec 18
Nivolumab for Metastatic Renal Cell Carcinoma: Results of a Randomized Phase II Trial.
Motzer RJ; Rini BI; McDermott DF; Redman BG; Kuzel TM; Harrison MR; Vaishampayan UN; Drabkin HA; George S; Logan TF; Margolin KA; Plimack ER; Lambert AM; Waxman IM; Hammers HJ; Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Dec 1
Motzer RJ; Rini BI; McDermott DF; Redman BG; Kuzel TM; Harrison MR; Vaishampayan UN; Drabkin HA; George S; Logan TF; Margolin KA; Plimack ER; Lambert AM; Waxman IM; Hammers HJ; Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2014 Dec 1
Foretinib (XL880): c-MET inhibitor with activity in papillary renal cell cancer.
Logan TF; Current oncology reports 2013 Apr
Logan TF; Current oncology reports 2013 Apr
A dose-escalation study of recombinant human interleukin-18 using two different schedules of administration in patients with cancer.
Robertson MJ; Kirkwood JM; Logan TF; Koch KM; Kathman S; Kirby LC; Bell WN; Thurmond LM; Weisenbach J; Dar MM; Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Jun 1
Robertson MJ; Kirkwood JM; Logan TF; Koch KM; Kathman S; Kirby LC; Bell WN; Thurmond LM; Weisenbach J; Dar MM; Clinical cancer research : an official journal of the American Association for Cancer Research 2008 Jun 1
Urticaria and angioedema in renal cell cancer patients treated with IL-2.
Logan TF; Strippoli G; Levine MI; Cancer investigation 2007
Logan TF; Strippoli G; Levine MI; Cancer investigation 2007
Interleukins 18 and 21: biology, mechanisms of action, toxicity, and clinical activity.
Logan TF; Robertson MJ; Current oncology reports 2006 Mar
Logan TF; Robertson MJ; Current oncology reports 2006 Mar
Oncology
American Board of Internal Medicine - Internal Medicine
Renal cell carcinoma; melanoma
Looking for patient care?
To schedule an appointment with a faculty member physician of IU School of Medicine, contact Indiana University Health at 888-484-3258 or use the physician finder by clicking the button below.